Lumida
/TRVI
⌘K
Trevi Therapeutics Inc

Trevi Therapeutics Inc

TRVI
$19.07USD↑+9.85%+1.71 today

MARKET CAP

2.7B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$17 – $20

52W RANGE

$7
$20

AI Summary

Stalk
Buy NowHigh

In a Stage 2 advancing trend with clear higher highs and higher lows, TRVI is undergoing a shallow pullback into the rising 9 and 20 EMAs, which have held as support. Despite overbought readings, volume and momentum behavior remain healthy, aligning with a speculative continuation approach. Medium-term bias is bullish, and current price behavior offers a tactical Buy Now opportunity on this pullback into the EMA support zone.

  • ↑Pro forma cash of $334M extends runway to 2030 after $162M raise.
  • ↑Phase II trials met primary endpoint, showing statistically significant cough reduction.
  • ↓Q1 net loss $0.09/share underscores ongoing unprofitability.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic cough and related disorders, particularly in patients suffering from idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Positioned at the forefront of a market with significant unmet medical needs, Trevi is advancing its drug candidate, Heduvia, through pivotal clinical trials aimed at securing regulatory approval and establishing its presence in a competitive landscape dominated by a need for effective chronic cough treatments.

Bull says

  • ↑Pro forma cash of $334M extends runway to 2030 after $162M raise.
  • ↑Phase II trials met primary endpoint, showing statistically significant cough reduction.
  • ↑Engaged with FDA; orphan drug designation strategy supports clear regulatory path.
  • ↑Addressable market ~228K patients (50–60% uncontrolled), signaling sizable demand.
  • ↑Analysts rate “Strong Buy” with $23.9 target, implying ~33% upside.
  • ↑High momentum and elevated institutional ownership suggest positive price catalysts.

Bear says

  • ↓Q1 net loss $0.09/share underscores ongoing unprofitability.
  • ↓Negative earnings power and poor profitability indicate lack of returns.
  • ↓Leverage risk elevated, threatening financial flexibility amid tight markets.
  • ↓Analyst revisions trending downward, reflecting waning expectations.
  • ↓High trial burn rate could necessitate further funding rounds.
  • ↓Competitive chronic cough space may erode Trevi’s future market share.

Investment themes with TRVI

Pharmaceuticals↓ -1.67%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-11-2026bullish

Transcript signals

Bull points

  • We ended the first quarter of 2026 with approximately $172 million in cash, cash equivalents, and marketable securities, which provides us with a strong financial foundation going forward.
  • The offering was well received, and we appreciated the strong support and participation we got from our current shareholders, and we are grateful that we were able to attract new investors to Trevi.
  • with the completion of this offering, we accomplished two major objectives. One, we removed any financial overhang when we reach critical high-value clinical endpoints. And two, we extended our cash runway into 2030.
Read full transcript analysis ›